PepGen Inc.
No SEC Form 4 filings for $PEPG in the last 30 days.
This article discusses the recent 14.3% drop in PepGen (PEPG) stock over the past four weeks. It suggests that despite this downturn, the stock might be poised for a trend reversal. The content will likely delve into technical or fundamental reasons for this potential change in trajectory.
H.C. Wainwright analyst Ananda Ghosh maintained a Buy rating on PepGen Inc. with a $20.00 price target. Ghosh believes PepGen's DM1 program is de-risked due to stronger underlying biology observed in treated patients, despite a modest average splicing correction skewed by an anomalous patient. The analyst anticipates significant upside from higher-dose cohorts, expecting materially higher splicing correction which could serve as a key value inflection point for the stock.
PepGen Ltd (NASDAQ:PEPG) shares dropped 44% after-hours following disappointing Phase 2 trial results for its myotonic dystrophy type 1 treatment, PGN-EDODM1. The drug showed an average splicing correction of 7.3% compared to placebo, with an outlier patient significantly impacting the overall mean. Despite the setback, the company plans to report data from a higher dose cohort in late 2026 and has sufficient funding into mid-2027.
